Ipilimumab Clinical Trial

CTLA-4–Blocking Immunotherapy With Ipilimumab For Advanced ...
CTLA-4–Blocking Immunotherapy With Ipilimumab for Advanced Melanoma phase III clinical trial that has shown that vaccination with the gp100 peptide improves outcome with ipilimumab trial in which the goal is further validation of biomarker data in the context of the E1609 ... Document Retrieval

Phase II trial Of ipilimumab-nivolumab Combo Shows Promise In ...
Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma 21 April 2015 Giving the two immunotherapies ipilimumab and nivolumab simultaneously yielded better treatment ... Retrieve Full Source

CTLA-4: The Unwanted Player In Cancer - YouTube
CTLA-4: The Unwanted Player in Cancer PATH3309 Cancer Pathology. Update on CTLA4 Clinical Trial - Dr. Rich Carvajal - Duration: 17:03. Jay Warmke 471 views. (ipilimumab): Targeted T-Cell Antibody for Metastatic Melanoma - Duration: ... View Video

Assessment Report For Yervoy (ipilimumab) Procedure No.: EMEA ...
Status, based on earlier ipilimumab clinical studies (MDXCTLA4-01, MDXCTLA4-02, MDX010-15, Results of the CA184024 phase 3 trial in melanoma patients treated with DTIC versus DTIC and ipilimumab were submitted to support the efficacy data obtained in the MDX010-20 study. ... Fetch Document

Fontolizumab - Wikipedia, The Free Encyclopedia
Fontolizumab (planned trade name HuZAF) A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint. [3] (Ipilimumab; Tremelimumab) CAT (Bertilimumab; Lerdelimumab; Metelimumab) ... Read Article

Ipilimumab For Melanoma Treatment - Skin Cancer
Ipilimumab has been tested in multiple clinical trials for many years and appears to finally be on the verge of FDA approval, perhaps as early as 2010. That's certainly good news for patients with melanoma, who have few options once the disease spreads to other areas of the body. ... Read Article

Nivolumab Plus Ipilimumab In Advanced Melanoma
Nivolumab plus Ipilimumab in Advanced Melanoma n engl j med 369;2 nejm.org july 11, 2013 123 E scape from immune surveillance is a recognized feature of cancer; therefore, ... Doc Retrieval

Finding Clinical Trials For Lung Cancer Treatment
Finding clinical trials for lung cancer can seem overwhelming. How do you begin to find a trial that meets your particular situation? ... Read Article

Immunotherapies In Lung Cancer: Can We Deliver On The Promise ...
Immunotherapies in Lung Cancer: Can We Deliver on the Promise? Ipilimumab, Anti-PD1, Anti-cancer Viruses, and Talactoferrin by Dr. Julie Brahmer ... Retrieve Content

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE ...
CONFIDENTIAL National Institute for Health and Clinical Excellence Page 2 of 33 Premeeting briefing – Ipilimumab for the treatment of previously treated unresectable malignant ... Read More

Viralytics To Commence Clinical Trial Of CAVATAKTM 04 ...
Viralytics to Commence Clinical Trial of CAVATAKTM Immunotherapy Combination (ipilimumab) in late-stage melanoma patients that will commence in early Q1 2015. The company-sponsored Phase 1b open label study is designed to evaluate the safety ... Content Retrieval

HIGHLIGHTS OF PRESCRIBING INFORMATION YERVOY ...
FULL PRESCRIBING INFORMATION YERVOY ® (ipilimumab) WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS YERVOY can result in severe and fatal immune-mediated adverse reactions. The safety of YERVOY was evaluated in Trial 1, a randomized, double-blind clinical trial ... View Doc

Prima BioMed Initiates Phase I Melanoma Study In Australia
Prima BioMed Ltd , a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial site for TACTI-mel, a Phase I clinical study in melanoma using its lead compound ... Read News

Thyroid Autoimmunity And Ophthalmopathy Related To Melanoma ...
She enrolled in a clinical trial with ipilimumab (10 mg/kg)/bevacizumab (7.5 mg/kg) after her disease progressed. She received the inter-feron-a therapy for 6 months. She was clinically euthyroid during the therapy. Her levels of TSH were ... Document Viewer

Ipilimumab For The Treatment Of Melanoma
Ipilimumab for the treatment of melanoma. Clinical pharmacology Ipilimumab is an IgG1 kappa immuno globulin produced in mammalian (Chinese hamster ovary) cell culture and has an approximate double-dummy clinical trial (MDX010-20) in ... Document Retrieval

New Melanoma Drugs
New Melanoma Drugs . and the role of the. Melanoma Research Foundation . and wrote a next generation concept for a Phase 3 combining clinical trial ipilimumab with PLX 4032, a selective BRAF inhibitor. Leadership of the MRF Breakthrough Consortium ... View Full Source

Cancer Center Open Clinical Trials - Susquehannahealth.org
Open Clinical Trials Trial # Title Recruitment Status Breast Cancer EA1131 A Randomized Phase III Post-Operative Trial of Platinum Based Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or IV Melanoma Recruiting patients ... Fetch Document

Clinical Challenges In The Management Of Melanoma
Clinical Research Program Leader, Melanoma Program There is evidence of this in the pivotal ipilimumab 020 trial. In that trial, Dr Sznol: In the absence of a clinical trial, I do things differently, starting with ipilimumab, ... Access Content

CTLA-4: The Unwanted Player In Cancer - YouTube
Update on CTLA4 Clinical Trial - Dr. Rich Carvajal - Duration: 17:03. Jay Warmke 465 views. 17:03 Ipilimumab Side Effect Management in Melanoma - Duration: 3:24. OncLiveTV 464 views. 3:24 Antigen presentation and CTL ... View Video

A Multicenter Treatment Protocol For Expanded Access Use Of ...
Clinical Trial Award Type Contract Date August 29, 2010 to September 2, 2012 Award Number 001659-00001 Sponsor Award Number CA184045 Award Contacts ipilimumab-bms-734016-subjects-unresectable. Title: A Multicenter Treatment Protocol for Expanded Access Use of Ipilimumab ... Get Document

Ipilimumab Criteria For Use
Ipilimumab (Yervoy) Criteria for Use. April 2012. VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives ... Get Content Here

Researchers Caution Against Combining Two Drugs For Treating ...
Researchers have found that combining ipilimumab (YervoyTM) and vemurafenib (Zelboraf®) can cause side effects for patients with metastatic melanoma ... View Video

Immune Correlates In A Phase II clinical trial With ...
Title: Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer ... Read More

Reference ID: 3831673 - Food And Drug Administration
Across the clinical trial experience in 188 patients with melanoma who received OPDIVO in combination with ipilimumab, in Trial 4 (n=94) and an additional dose-finding study (n=94), fatal immune-mediated pneumonitis occurred in 0.5% (1/188) of patients. ... Fetch Full Source

Ipilimumab - Springer
Ipilimumab Abstract Ipilimumab (BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDX-CTLA4) is an anti-CTLA-4 monoclonal antibody, which is in development ... Document Viewer